New York, NY—October 22, 2003
Hospital for Special Surgery announced that it has recently received more than $8.1 million in grants from the National Institutes of Health (NIH) to fund basic and clinical research activities. Drs. Mary Crow, Kyriakos Kirou, Luminata Pricop, and Jane Salmon are the principal investigators for these grants.
According to Dr. Francesco Ramirez, Chief Scientific Officer of the Hospital, “These grants not only foster and support our campaign for research, but I am confident will lead to unprecedented advances in the treatment of musculoskeletal problems.”
Dr. Mary Crow, Professor of Medicine, Autoimmunity and Inflammation Research Program, received two different grants totaling $1.5+ million from the National Institutes of Health. One 4-year grant was awarded to investigate premature atherosclerosis in rheumatic disease. The other 2-year grant aims to identify rheumatic disease genes.
Dr. Kyriakos A. Kirou, Assistant Scientist in the Autoimmunity and Inflammation Research Program, received a 5-year grant of $600,000+ from the National Institutes of Health to study how CD40 Ligand--a key molecule in immunology--is regulated at the posttranscriptional level that is after its message (mRNA) is generated in a T-lymphocyte. Additionally, lymphocytes from patients with lupus will be examined for evidence of abnormal posttranscriptional regulation of CD40 Ligand. As this molecule is believed to play an important role in lupus, a better understanding of its regulation will help us develop better therapies for this and perhaps other related diseases.
Dr. Luminita Pricop, Associate Member in the Autoimmunity and Inflammation Research Program, received a 2-year grant from the National Institutes of Health for $170,000 to study the role of a subset of peripheral blood cells in T cell activation.
Dr. Jane Salmon, attending rheumatologist and Senior Scientist in the Autoimmunity and Inflammation Research Program, received a 5-year grant of $5.7+ million from the National Institutes of Health to identify predictors of pregnancy outcomes in patients with lupus and antiphospholipid antibodies.
About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 2 in rheumatology by U.S. News & World Report (2016-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.